Modulating mTOR Signaling as a Promising Therapeutic Strategy for Atherosclerosis

For more than a decade, atherosclerosis has been one of the leading causes of death in developed countries. The issue of treatment and prevention of the disease is especially acute. Despite the huge amount of basic and clinical research, a significant number of gaps remain in our understanding of th...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-01, Vol.23 (3), p.1153
Main Authors: Poznyak, Anastasia V, Sukhorukov, Vasily N, Zhuravlev, Alexander, Orekhov, Nikolay A, Kalmykov, Vladislav, Orekhov, Alexander N
Format: Article
Language:English
Subjects:
Amino acids
Apoptosis
Arteriosclerosis
Atherogenesis
Atherosclerosis
Atherosclerosis - drug therapy
Atherosclerosis - metabolism
Atherosclerosis - pathology
Autophagy
Biosynthesis
Cell growth
Cyclin-dependent kinases
Gene expression
Growth factors
Health services
Humans
Hypoxia
Immunosuppressive Agents - therapeutic use
Insulin resistance
Kinases
Metabolism
Phosphorylation
Protein synthesis
Proteins
Rapamycin
Review
Signal Transduction
Sirolimus - therapeutic use
TOR protein
TOR Serine-Threonine Kinases - chemistry
TOR Serine-Threonine Kinases - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:For more than a decade, atherosclerosis has been one of the leading causes of death in developed countries. The issue of treatment and prevention of the disease is especially acute. Despite the huge amount of basic and clinical research, a significant number of gaps remain in our understanding of the pathogenesis of atherosclerosis, and only their closure will bring us closer to understanding the causes of the disease at the cellular and molecular levels and, accordingly, to the development of an effective treatment. One of the seemingly well-studied elements of atherogenesis is the mTOR signaling pathway. However, more and more new details are still being clarified. Therapeutic strategies associated with rapamycin have worked well in a number of different diseases, and there is every reason to believe that targeting components of the mTOR pathway may pay off in atherosclerosis as well.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms23031153